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Dear Editor,
The emergence of the Middle East Respiratory Syndrome
Coronavirus (MERS-CoV) in 2012 was associated with variable rate of
asymptomatic infection but no asymptomatic cases were reported
among pregnancy [1]. The newly emerging 2019 novel coronavirus
(2019-nCoV), later named SARS-CoV-2 is the causative agent of the
COVID-19. SARS-CoV-2 was identified initially in Wuhan, China. Since
its first description in December 2019, the total number of cases as
reported by the World Health Organization (WHO) had reached
191,127confirmed cases on February 18, 2020, with 7807 deaths [2].
The clinical picture and radiographic presentations were recently de-
scribed [3,4] and the clinical picture in nine pregnant women [5] were
similar to non-pregnant women [3,4]. One study showed that 15
pregnant patients with COVID-19 had mild disease [6]. All of the
pregnant patients in one study and 66.7% of pregnant COVID-19 pa-
tients had C-section, moreover all the newborn survived [5,6]. How-
ever, 4 of 9 (44%) pregnant COVID-19 patients had premature delivery
[5]. In a previous study of MERS-CoV, there were 11 pregnant women
[7]. A comparison between MERS-CoV and COVID-19 cases in preg-
nancy is shown in Table 1. There was no difference in the age group of
the patients, however, the gestational age was lower among MERS-CoV
than COVID-19 patients. Of the MERS-CoV cases in pregnancy, 63.6%
required intensive care unit admission and this is comparable to 50% of
SARS pregnant women [8]. There was no mention about the death rate
among pregnant women with COVID-19, however, the case fatality rate
among MERS-pregnant patients was about 35% and was not statistically
different when compared to the overall MERS case fatality rate [7]. In
the MERS cases, 40% had C-section and this is much lower than 100%
C-section rate in the case of COVID-19. This difference may reflect a
variance in the practices between different countries. Another differ-
ence is the high fetal demise rate of 30% among pregnant women with
MERS compared to 0% among COVID-19. The fetal demise rate among
12 pregnant women with SARS was 25% [8]. Thus, similar to the dif-
ference in the clinical presentation and course among SARS, MERS-CoV
and COVID-19, there is also differences in the outcome and course of
pregnant women with these coronaviruses’ infection. Understanding
the impact of COVID-19 on pregnancy and outcome would guide
healthcare authorities and public health on further risk mitigation and
advise for pregnant women around the world.
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Table 1
A comparison between pregnant women with MERS-CoV and COVID-19.
MERS-CoV
[7]
COVID-19
[5]
COVID-19
[6]
P value
Number of patients 11 9 15
Mean Age (year) 33.2 29.9 32 0.127
Mean Gestational age
(weeks)
28 37.1 32 0.01
ICU admission (%) 63.6 – 0
Maternal survival (%) 72.7 – 100
Fetal survival (%) 70 100 100
C-section, n (%) 40 100 66.7
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